Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Biohaven Pharmaceutical Holding Co. Ltd.
DescriptionProdrug formulation of riluzole, a glutamate modulating agent
Molecular Target Not applicable
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase III
Standard IndicationAtaxia
Indication DetailsTreat hereditary spinocerebellar ataxia; Treat spinocerebellar ataxia
Regulatory Designation U.S. - Orphan Drug (Treat spinocerebellar ataxia)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today